Antineoplastic Agents, Alkylating
Research News and Information

Sunday, November 22, 2009

Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience.

29 Nov 2009 BACKGROUND: The prognosis for recurrent/progressive Ewing sarcoma (ES) remains poor. Pre-clinical, adult phase I and II trials have demonstrated the combination of irinotecan and temozolomide to have schedule-dependent synergy and significant ... Read more...

Early development of acute myeloid leukemia following treatment of osteosarcoma: a case report and review of the literature.

29 Sep 2009 We report a case of treatment-related acute myeloid leukemia (t-AML) in a 16-year-old male following treatment for osteosarcoma (OS). He had been treated with a protocol comprising neoadjuvant chemotherapy, definitive surgery with wide excision and ... Read more...

Promoter methylation and expression analysis of MGMT in advanced pediatric brain tumors.

29 Sep 2009 Insufficient response to oral temozolomide (TMZ) in children with brain tumor may depend on the repair-action of inducible O6-methylguanine-DNA methyltransferase (MGMT). To investigate the clinical relevance of MGMT expression, we analyzed MGMT ... Read more...

Latest indexed articles for 'Antineoplastic Agents, Alkylating'

These are the very latest articles for this heading:

• Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience. 29 Nov 2009
• Early development of acute myeloid leukemia following treatment of osteosarcoma: a case report and review of the literature. 29 Sep 2009
• Promoter methylation and expression analysis of MGMT in advanced pediatric brain tumors. 29 Sep 2009
• Stem-cell collection before high-dose therapy for multiple myeloma: time has come to raise the standards! 29 Sep 2009
• Non-Hodgkin lymphoma following temozolomide. 29 Sep 2009
• [Autologous stem cell transplantation in multiple myeloma - pro] 14 Sep 2009
• Recurrent PNET with MGMT methylation responds to temozolomide. 30 Aug 2009
• Population-based study of pseudoprogression after chemoradiotherapy in GBM. 30 Aug 2009
• [Appropriate hemodialysis scheduling based on therapeutic drug monitoring of carboplatin in a patient with lung cancer and chronic renal failure] 30 Aug 2009
• [A case of stage IV breast cancer with large cancer ulcer responding to combination therapy of capecitabine and medroxyprogesterone acetate and cyclophosphamide] 30 Aug 2009
• Interaction of ionizing radiation and ZRBA1, a mixed EGFR/DNA-targeting molecule. 30 Aug 2009
• A rare case of aplastic anemia caused by temozolomide. 30 Aug 2009
• Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts. 30 Aug 2009
• Hemorrhagic cystitis in a child with Hodgkin lymphoma and ataxia-telangiectasia after cyclophosphamide. 30 Aug 2009
• Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. 24 Aug 2009
• Cellulose-based dual graft molecular brushes as potential drug nanocarriers: stimulus-responsive micelles, self-assembled phase transition behavior, and tunable crystalline morphologies. 8 Aug 2009
• Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. 2 Aug 2009
• Perioperative high-dose-rate brachytherapy in the treatment of recurrent malignant gliomas. 2 Aug 2009
• Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. Aug 2009
• [Cerebellopontine angle meningeal melanocytoma: a benign tumor?] 30 Jul 2009

See a longer list of these articles.

Technical information about 'Antineoplastic Agents, Alkylating'

Definition: A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)

Registry Number: 0

Descriptor UI: D018906

Alternative terms: Antineoplastic Agents, Alkylating; Antineoplastic Alkylating Agents; Alkylating Agents, Antineoplastic; Antineoplastic Drugs, Alkylating; Antineoplastics, Alkylating; Alkylating Antineoplastic Drugs; Alkylating Drugs, Antineoplastic; Antineoplastic Alkylating Drugs; Drugs, Antineoplastic Alkylating; Alkylating Antineoplastic Agents; Alkylating Antineoplastics;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D27.505.519.124.035; D27.505.954.248.150; D27.888.569.035.035;

History Note: 96